Topical Pain Killers is anticipated to have CAGR of ~7.2% over 2019-2028. The rise in prevalence of arthritis, diabetic neuropathy, cancer and other bone- related conditions which cause pain would boost the industry in the forecast period. The increase in adoption of topical pain relief products due to the advantage over oral pain relievers are observed is anticipated to help the industry grow. The surge in geriatric population would help the industry flourish. The rise in the pain caused due to sports activities is expected to grow in the coming years. The advancement and development of online platform for the availability of topical therapeutics and better potential in untapped markets in the emerging economies are anticipated to flourish over the forecast period.

Top Driver: Rise in the chronic conditions to boost the industry

Topical Pain Killers is projected to grow with the increase in the conditions such as cancer, diabetic neuropathy, arthritis and other bone related disorders which needs assistance of topical agents would help the industry to grow in the near future. According to the Center for Disease Prevention and Control, it is estimated that people aged 18 to 44 years, 7.1% ever reported doctor-diagnosed arthritis. Furthermore, by 2040, an estimated 78 million (26%) US adults aged 18 years or older are estimated to have doctor-diagnosed arthritis. This increase in the number of individuals who are expected to use the topical pain killers and the growth in other bone-related issue population would propel the market.

Cream to Make Crucial Contribution to Growth of Global Topical Pain Killers Market

Among Formulation segments of the global Topical Pain Killers market, creams segment is expected to gain maximum shares in the forecast period. This owes to the advantage posed by cream formulation which include, ease in application, and better absorption due to oily base, which would help the industry grow in the coming years. It offers lesser side effects, gave higher success rates. The longer shelf life and ease in availability would help the industry boost in the coming years. Furthermore, spray segment is expected to experience highest CAGR due to the application on the targeted area and hence would help the industry flourish.

 Increase in patient population to Benefit North America Market

North America is experiencing highest revenue growth than any other country and is anticipated to grow further in the near future. This owes to the surge in the patient population having pain which can be managed using topical pain killer. In addition, Asia-Pacific is anticipated to experience highest CAGR, the market during the analysis period, due to higher population base. The rise in disposable income in the region, and increase in patient awareness about topical pain relief products is anticipated to help the industry grow. Moreover, Asia is a large continent, and has emerged as the site having the highest number of life-threatening diseases, would experience highest CAGR and hence is anticipated to help the industry grow in the forecast period.

The COVID-19 disease spread has drastically affected various industries causing a downturn in their revenues. This owes to the enforcement of the government to lockout everything unless the situation is under control. However, social distancing can be carried out and hence cope up with the current pandemic. The topical pain killers market however remain less affected due to the advantage posed by the formulation.

Players to Focus on advanced Topical Pain Killers

The global Topical Pain Killers market leaders include Topical BioMedics, Inc., Novartis AG, GlaxoSmithKline Plc., Troy Healthcare, LLC, Emami Group, Chattem, Inc., Performance Health Technologies, Inc., Exzell Pharma, Sun Pharmaceutical Industries Ltd., Reckitt Benckiser Group Plc., Sanofi S.A., Johnson & Johnson, AdvaCare Pharma, Nestle S.A. and Pfizer Inc.

Topical BioMedics, Inc.: In July 2020, Topical BioMedics, Inc., the makers of Topricin Pain Relief and Healing Creams, had expanded its product line with the launch of its new MyPainAway formulas, which address specific ailments and pain issues. The company has initially rolled out two formulas which include MyPainAway Fibro Cream and MyPainAway After-Burn Cream with more formulas slated

Novartis AG: In June 2014, Novartis India, OTC Division, had launched topical body pain reliever, Voltaren Emulgel, in India. It has Emulgel formulation that provides instant relief from body pain, speeding up recovery. Voltaren’s triple action formula gets absorbed fast, penetrates deep to the source of pain and reduces inflammation, thus providing relief and recovery from body pain. Its uniquely developed Emulgel formulation which is a combination of cream and gel, helps the active ingredient to rapidly penetrate deep into the skin and reach the source of pain to reduce the inflammation and provide speedy recovery.

Sun Pharmaceutical Industries Ltd.: In September 2018, Sun Pharma Consumer Healthcare, a division of Sun Pharmaceutical Industries Ltd announced the launch of Volini Maxx, India’s strongest pain relief spray.

Scope of the Report

By Therapeutic Class

• Opioids
• Non-Opioids

By Type

• Prescription Pain Relief
• Over-the-counter (OTC) Pain Relief

By Formulation

• Cream
• Patch
• Gel
• Spray
• Others

By Region

• North America
• Europe
• Asia Pacific
• LAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.